Neuhofer J, Fritsch P
Hautarzt. 1984 Sep;35(9):459-63.
A pilot study with the anti-leprosy agent clofazimine was conducted on seven patients with cheilitis granulomatosa or complete Melkersson-Rosenthal syndrome. Beneficial effects were observed in all patients, dependent on the degree of the clinical expression of the disease: the variable attacks of lip swelling, characteristic for the edematous phase of this disease, were suppressed promptly and completely in all patients. Persistent residual swelling of the lips, caused by cellular inflammatory infiltrates, which was present in four patients prior to therapy, responded much less rapidly and--in three out of four--only incompletely. After drug withdrawal, four patients remained free of symptoms for periods ranging from 5 to 45 months; the remaining three patients relapsed after intervals of 3-18 months. The mode of action clofazimine takes in cheilitis granulomatosa is not understood at the present time but is likely to be linked to the phagocytosis-stimulating effect of this drug on macrophages.
对7例患有肉芽肿性唇炎或完全型梅克尔森－罗森塔尔综合征的患者进行了抗麻风药氯法齐明的一项初步研究。在所有患者中均观察到有益效果，这取决于疾病临床表现的程度：该疾病水肿期特有的唇部肿胀的反复发作，在所有患者中均迅速且完全得到抑制。由细胞炎性浸润引起的唇部持续性残余肿胀，在4例治疗前的患者中存在，其反应要慢得多，并且在4例中有3例仅部分消退。停药后，4例患者在5至45个月的时间内无症状；其余3例患者在3至18个月的间隔后复发。目前尚不清楚氯法齐明在肉芽肿性唇炎中的作用方式，但可能与该药物对巨噬细胞的吞噬刺激作用有关。
